Replies to post #93432 on Biotech Values

[DewDiligence]

Re: IDIX’s newest director

Ms. Howson fills the open seat on the BoD that IDIX has had since Jan 2010 (when Pamela Thomas-Graham left to take a position at Credit Suisse). With Howson’s appointment, independent directors now comprise a majority (5 of 9 seats) on IDIX’s BoD.

If what IDIX wanted was a director with experience in biotech partnerships and M&A transactions, a better pick than Ms. Howson would be hard to find. She has held senior business-development positions at BMY, LEXG, and SmithKline Beecham (now part of GSK). Howson also has an engineering degree from Technion in Israel, one of the world’s premiere academic institutions.